Treatment of Tuberculosis Meningitis

Standard Treatment Regimen

The British Thoracic Society recommends a 12-month treatment duration for TB meningitis, consisting of rifampicin and isoniazid, supplemented by pyrazinamide and a fourth drug for the first 2 months, plus adjunctive corticosteroids tapered over 6-8 weeks 1, 2
The initial intensive phase consists of rifampicin 10 mg/kg daily, isoniazid 5 mg/kg daily, pyrazinamide 35 mg/kg daily, and a fourth drug, either ethambutol 15 mg/kg daily or streptomycin 15 mg/kg daily, for 2 months 1, 2, 3

The American Thoracic Society and the British Thoracic Society recommend adjunctive corticosteroid therapy for all patients with TB meningitis, with strong evidence for moderate to severe disease, using dexamethasone 6-12 mg/day or prednisolone/prednisone 60-80 mg/day, tapered over 6-8 weeks 1, 2, 3

Isoniazid, pyrazinamide, and ethionamide have good CSF penetration, while rifampicin has moderate penetration, and streptomycin and ethambutol have poor penetration, except in early treatment stages when meninges are inflamed 1, 2, 3

The American Academy of Pediatrics recommends a 12-month treatment duration for children, with weight-based dosing, using rifampicin, isoniazid, pyrazinamide, and a fourth drug, either ethionamide or an aminoglycoside, for the first 2 months, followed by rifampicin and isoniazid for 10 additional months 1, 2, 3
Pyridoxine supplementation is recommended for HIV-infected, malnourished, or breast-fed children 4

For isoniazid mono-resistance, treatment consists of rifampicin, pyrazinamide, ethambutol, and a fluoroquinolone for 12-15 months, with an injectable agent added for extensive disease 4
For rifampicin mono-resistance, treatment consists of isoniazid, pyrazinamide, ethambutol, fluoroquinolone, and an injectable agent for 18 months 4
For MDR-TB meningitis, treatment consists of an injectable drug for 4-6 months, with a total treatment duration of 18-24 months 4
For XDR-TB, treatment consists of a minimum of 24 months with less effective drugs 4

Regular neurological assessment and repeated lumbar punctures are necessary to monitor CSF cell count, glucose, and protein, especially early in therapy 1, 2
Hepatotoxicity monitoring is essential, given the hepatotoxic potential of isoniazid, rifampicin, and pyrazinamide 1, 2

Inadequate treatment duration is a common and dangerous error, with TB meningitis requiring 12 months of treatment, not 6 months 1, 2
Selecting drugs with insufficient CSF penetration, omitting corticosteroids in moderate to severe disease, and failing to use a fourth drug when local isoniazid resistance exceeds 4% are additional pitfalls to avoid 1, 2, 3

Standard 12‑month regimen – For CNS tuberculosis without documented drug resistance, initiate a 2‑month intensive phase with isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by a 10‑month continuation phase with isoniazid + rifampicin. Daily dosing is strongly preferred over intermittent schedules. (Strong recommendation) 5
Minimum effective duration – Treatment courses shorter than 9 months (e.g., a 6‑month regimen) are inadequate for CNS disease and are associated with treatment failure and relapse; a 12‑month duration is strongly preferred. (Strong recommendation) 5

Mortality reduction – Adding corticosteroids to antitubercular therapy lowers overall mortality by approximately 25 % (relative risk 0.75) and is strongly recommended for all patients with CNS tuberculosis, irrespective of disease severity or HIV status. (Strong recommendation) 6
Dexamethasone dosing (preferred) – Begin with 12 mg IV daily (or 0.4 mg/kg/day, max 12 mg) for 3 weeks, then taper gradually over the next 3 weeks, completing a 6‑week course. (Strong recommendation) 6
Prednisone alternative – If IV access is unavailable, start oral prednisone 60 mg daily for 4 weeks, then taper to 30 mg daily for 4 weeks, 15 mg daily for 2 weeks, and 5 mg daily for the final week. (Strong recommendation) 6
Subgroup benefit – Patients presenting with moderate (lethargic) disease experience the greatest mortality benefit, with death rates falling from ~40 % to ~15 % when dexamethasone is used. (Strong recommendation) 6

Avoid abbreviated therapy – Do not prescribe a 6‑month antitubercular regimen for CNS infection; such duration is only validated for pulmonary disease and leads to higher relapse rates. (Strong recommendation) 5
Complete steroid taper – Abrupt discontinuation of corticosteroids should be avoided; a full 6–8‑week tapered course is required to prevent adrenal insufficiency. (Strong recommendation) 6